Bioactive metabolites derived from the phylum Actinobacteria represent many of the existing antimicrobial drugs. Compared with other bacterial pathogens, direct preliminary screening by diffusion assays is a limiting factor against Mycobacterium tuberculosis (Mtb) and different methodologies have been used to improve the search for new molecules. However, the concern remains that most of the previously discovered molecules replicate by conventional procedures. The combination of multidisciplinary approaches with new technologies could advance the discovery of new leads against Mtb like considering the unexplored Actinobacteria jointly with selective and integrative procedures.

来自放线菌门的生物活性代谢物代表了许多现有的抗微生物药物。与其他细菌病原体相比，通过扩散试验进行的直接初步筛选是针对结核分枝杆菌( Mtb )的限制因素，并且已使用不同的方法来改进对新分子的搜索。然而，令人担忧的是，大多数先前发现的分子通过常规程序进行复制。多学科方法与新技术的结合可以促进对Mtb的新线索的发现，例如将未探索的放线菌与选择性和综合程序结合起来考虑。